Evidence map›Paper›PMID 32988688›Full record

ArticleVaccine2020

Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.

Maëlle Detoc, Sébastien Bruel, Paul Frappe, Bernard Tardy, Elisabeth Botelho-Nevers, Amandine Gagneux-Brunon

Abstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 374 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. COVID-19 clinical trial participation and awareness in Texas.Human vaccines & immunotherapeutics · 2024
    Article
  18. Article
  19. Article
  20. Article

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maëlle DetocCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France.
Sébastien BruelCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France; Department of General Practice, Faculté de Médecine Jacques Lisfranc, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; PRESAGE Insitute, Université de Lyon, Saint-Etienne, France.
Paul FrappeCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France; Department of General Practice, Faculté de Médecine Jacques Lisfranc, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; PRESAGE Insitute, Université de Lyon, Saint-Etienne, France.
Bernard TardyCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France.
Elisabeth Botelho-NeversCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; PRESAGE Insitute, Université de Lyon, Saint-Etienne, France.
Amandine Gagneux-BrunonCentre d'investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; PRESAGE Insitute, Université de Lyon, Saint-Etienne, France. Electronic address: amandine.gagneux-brunon@chu-st-etienne.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial.

methodsWe conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial.

resultsThree thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4% of the respondents. According to their statements, 2.512 participants (77.6%, 95% CI 76.2-79%) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9-49.3%) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial.

conclusionsNearly 75% and 48% of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake.

Indexed as

AdultAgedAged, 80 and overAge FactorsBetacoronavirusClinical Trials as TopicCoronavirus InfectionsCOVID-19COVID-19 VaccinesFemaleFranceHealth PersonnelHumansIntentionMaleMiddle AgedCOVID-19 VaccinesViral VaccinesCOVID-19PandemicsSARS-CoV-2VaccineVaccine hesitancy

Identifiers

PMID32988688
PMCPMC7498238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.